6WI7
| RING1B-BMI1 fusion in closed conformation | Descriptor: | 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID, E3 ubiquitin-protein ligase RING2, Polycomb complex protein BMI-1 chimera, ... | Authors: | Cho, H.J, Cierpicki, T. | Deposit date: | 2020-04-08 | Release date: | 2021-04-14 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (1.702 Å) | Cite: | Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nat.Chem.Biol., 17, 2021
|
|
6WI8
| |
8SK7
| Cryo-EM structure of designed Influenza HA binder, HA_20, bound to Influenza HA (Strain: Iowa43) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, HA_20 minibinder (RFdiffusion-designed), ... | Authors: | Borst, A.J, Bennett, N.R. | Deposit date: | 2023-04-18 | Release date: | 2023-06-14 | Last modified: | 2023-09-13 | Method: | ELECTRON MICROSCOPY (2.93 Å) | Cite: | De novo design of protein structure and function with RFdiffusion. Nature, 620, 2023
|
|
8T5K
| Crystal structure of STING CTD in complex with BDW-OH | Descriptor: | Stimulator of interferon genes protein, {[(4S)-8,9-dimethylthieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3-yl]sulfanyl}acetic acid | Authors: | Li, Y, Li, P, Sun, D. | Deposit date: | 2023-06-13 | Release date: | 2023-07-12 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Structural and Biological Evaluations of a Non-Nucleoside STING Agonist Specific for Human STING A230 Variants. Biorxiv, 2023
|
|
8T5L
| Crystal structure of STING CTD in complex with 2'3'-cGAMP | Descriptor: | Stimulator of interferon genes protein, cGAMP | Authors: | Li, Y, Li, P, Sun, D. | Deposit date: | 2023-06-13 | Release date: | 2023-07-12 | Last modified: | 2023-10-25 | Method: | X-RAY DIFFRACTION (2.01 Å) | Cite: | Structural and Biological Evaluations of a Non-Nucleoside STING Agonist Specific for Human STING A230 Variants. Biorxiv, 2023
|
|
8E9F
| |
5WTK
| Crystal structure of RNP complex | Descriptor: | CRISPR-associated endoribonuclease C2c2, RNA (58-MER) | Authors: | Liu, L, Wang, Y. | Deposit date: | 2016-12-13 | Release date: | 2017-02-08 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (2.651 Å) | Cite: | Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities Cell, 168, 2017
|
|
5GO7
| Linear tri-ubiquitin | Descriptor: | D-ubiquitin, Ubiquitin | Authors: | Gao, S, Pan, M, Zheng, Y. | Deposit date: | 2016-07-26 | Release date: | 2016-11-02 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.801 Å) | Cite: | Monomer/Oligomer Quasi-Racemic Protein Crystallography J.Am.Chem.Soc., 138, 2016
|
|
5GOC
| Lys11-linked diubiquitin | Descriptor: | D-ubiquitin, SODIUM ION, Ubiquitin | Authors: | Gao, S, Pan, M, Zheng, Y. | Deposit date: | 2016-07-26 | Release date: | 2016-11-02 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.733 Å) | Cite: | Monomer/Oligomer Quasi-Racemic Protein Crystallography J.Am.Chem.Soc., 138, 2016
|
|
8THL
| |
5GOI
| Lys48-linked di-ubiquitin | Descriptor: | D-ubiquitin, Ubiquitin | Authors: | Gao, S, Pan, M, Zheng, Y, Liu, L. | Deposit date: | 2016-07-27 | Release date: | 2016-11-02 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.594 Å) | Cite: | Monomer/Oligomer Quasi-Racemic Protein Crystallography J.Am.Chem.Soc., 138, 2016
|
|
8THK
| |
4YQH
| 2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A | Descriptor: | 2-[2-(4-phenyl-1H-imidazol-2-yl)ethyl]quinoxaline, MAGNESIUM ION, ZINC ION, ... | Authors: | Burdi, D, Herman, L, Wang, T. | Deposit date: | 2015-03-13 | Release date: | 2015-04-29 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.308 Å) | Cite: | Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A. Bioorg.Med.Chem.Lett., 25, 2015
|
|
4YS7
| Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imidazo[4,5-f]quinoline (compound 39) with PDE10A | Descriptor: | 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imidazo[4,5-f]quinoline, MAGNESIUM ION, ZINC ION, ... | Authors: | Burdi, D.F, Herman, L, Wang, T. | Deposit date: | 2015-03-16 | Release date: | 2015-04-29 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2.502 Å) | Cite: | Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A. Bioorg.Med.Chem.Lett., 25, 2015
|
|
5GOB
| Lys6-linked di-ubiquitin | Descriptor: | D-ubiquitin, Ubiquitin | Authors: | Gao, S, Pan, M, Zheng, Y, Liu, L. | Deposit date: | 2016-07-26 | Release date: | 2016-11-02 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.153 Å) | Cite: | Monomer/Oligomer Quasi-Racemic Protein Crystallography J.Am.Chem.Soc., 138, 2016
|
|
5WTJ
| Crystal structure of an endonuclease | Descriptor: | CRISPR-associated endoribonuclease C2c2 | Authors: | Liu, L, Wang, Y. | Deposit date: | 2016-12-13 | Release date: | 2017-02-08 | Last modified: | 2017-08-30 | Method: | X-RAY DIFFRACTION (3.503 Å) | Cite: | Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities Cell, 168, 2017
|
|
3FD5
| |
8HOG
| Crystal structure of Bcl-2 in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOH
| Crystal structure of Bcl-2 G101V in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOI
| Crystal structure of Bcl-2 D103Y in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, FORMIC ACID, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
4IKP
| Crystal structure of coactivator-associated arginine methyltransferase 1 with methylenesinefungin | Descriptor: | (2S,5S)-2,6-diamino-5-{[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl}hexanoic acid, GLYCEROL, Histone-arginine methyltransferase CARM1, ... | Authors: | Dong, A, Dombrovski, L, He, H, Ibanez, G, Wernimont, A, Zheng, W, Bountra, C, Arrowsmith, C.H, Edwards, A.M, Brown, P.J, Min, J, Luo, M, Wu, H, Structural Genomics Consortium (SGC) | Deposit date: | 2012-12-27 | Release date: | 2013-02-13 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion. Elife, 8, 2019
|
|
5YU9
| Crystal structure of EGFR 696-1022 T790M in complex with Ibrutinib | Descriptor: | 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one, CHLORIDE ION, Epidermal growth factor receptor | Authors: | Yan, X.E, Yun, C.H. | Deposit date: | 2017-11-21 | Release date: | 2017-12-27 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget, 7, 2016
|
|
8WRM
| XBB.1.5 spike protein in complex with ACE2 | Descriptor: | Processed angiotensin-converting enzyme 2, Spike glycoprotein | Authors: | Feng, L.L, Feng, L.L. | Deposit date: | 2023-10-15 | Release date: | 2023-12-06 | Last modified: | 2024-03-20 | Method: | ELECTRON MICROSCOPY (4.34 Å) | Cite: | Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. Plos Pathog., 19, 2023
|
|
8WRO
| XBB.1.5.10 spike protein in complex with ACE2 | Descriptor: | Processed angiotensin-converting enzyme 2, Spike glycoprotein,Spike glycoprotein,Spike glycoprotein,Fusion protein | Authors: | Feng, L.L, Feng, L.L. | Deposit date: | 2023-10-15 | Release date: | 2023-12-06 | Last modified: | 2024-03-20 | Method: | ELECTRON MICROSCOPY (3.9 Å) | Cite: | Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. Plos Pathog., 19, 2023
|
|
8WTD
| XBB.1.5.10 RBD in complex with ACE2 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Angiotensin-converting enzyme 2, Spike protein S2' | Authors: | Feng, L.L, Feng, L.L. | Deposit date: | 2023-10-18 | Release date: | 2023-12-13 | Last modified: | 2024-03-20 | Method: | ELECTRON MICROSCOPY (3.06 Å) | Cite: | Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. Plos Pathog., 19, 2023
|
|